Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13281290 | 0.89 | MEN1 (0.52) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL15475326 | 0.81 | ALDH1A1 (0.45) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL15475325 | 0.81 | ALDH1A1 (0.45) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL13464291 | 0.76 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL18844027 | 0.73 | KMT2A (0.74) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL12011418 | 0.72 | MEN1 (0.42) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL15475279 | 0.71 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL31501094 | 0.71 | NPC1 (0.55) | MAPTALDH1A1LMNAHPGDKDM4E | |
| SCHEMBL13464273 | 0.70 | KDM4E (0.47) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL13557434 | 0.69 | KDM4E (0.55) | MEN1KMT2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284298-B2 | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-15 | — | — | US | disclosed |
| US-9284298-B2 | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-15 | — | — | US | disclosed |
| US-20140051708-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-20 | — | — | US | disclosed |
| US-20140051708-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-20 | — | — | US | disclosed |
| US-20140051708-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-20 | — | — | US | disclosed |
| WO-2012139930-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051708-A1 | PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K6 | MEN1 4441/4885KMT2A 2034/4885MAPT 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.